As global EAP and IIS programs grow in scale and complexity, spreadsheets, email, and shared drives can create operational, security, and compliance risks. Discover why purpose-built, validated technology provides a more scalable, traceable, and controlled foundation for global programs.

The conversations at Operationalize: Expanded Access Programs (OEAP) West in San Francisco made one thing abundantly clear: Expanded Access Programs (EAPs) are no longer viewed as exceptional, one-off initiatives.

For thousands of patients around the world, the difference between hope and heartbreak often comes down to time.

As expanded access and managed access programs become increasingly important components of patient access strategy, biopharmaceutical companies face a critical question: which capabilities should be developed internally, and which are best supported through external expertise and technology partners?

For patients facing serious or life-threatening conditions, waiting for full regulatory approval of a promising therapy is often not an option. Expanded Access Programs (EAPs), sometimes referred to as compassionate use programs, have long provided a regulatory pathway for patients to receive investigational treatments outside of clinical trials.

Expanded Access Programs (EAPs) - also known as compassionate use—play a critical role in bridging the gap between clinical development and patient need.

Expanded Access Programs (EAPs) are a critical pathway for patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials.